Nuevolution Announces Collaboration in Drug Discovery with Boehringer Ingelheim
|| Print ||
|Tuesday, 20 September 2011 10:00 (UTC + 2)|
Partnership to use Nuevolution's Chemetics® Technology for Lead Discovery
Copenhagen, September 20, 2011 / B3C newswire / – Nuevolution A/S today announced that it has entered into collaboration with Boehringer Ingelheim, using Nuevolution’s proprietary Chemetics® drug discovery technology. Within the framework of the collaboration, hundreds of millions of diverse small molecules will be screened to discover and advance drug candidates against drug targets of interest to Boehringer Ingelheim.
The Chemetics® platform uses innovative
Under the terms of the agreement, Boehringer Ingelheim will provide
“We are very pleased about the expansion of our partnership portfolio by entering into this drug discovery collaboration with Boehringer Ingelheim,” said Alex Gouliaev, CEO of Nuevolution A/S. “We are looking forward to successfully tackle further challenging targets in collaboration with the innovative scientists at Boehringer Ingelheim.”
Nuevolutions library collection currently exceeds 1 billion small molecule compounds and synthetic biologics for screening.
Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreements with Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma and now Boehringer Ingelheim. Nuevolution has also entered into a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) aiming at discovery and development of novel small molecule drugs against epigenetic factors. This 24 MDKK budget joint venture project is supported by The Danish National Advanced Technology Foundation.
Nuevolution has demonstrated the power of Chemetics® by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.